Detailed Information
Cited 0 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
Overall survival (OS) by response to first-line (1L) induction treatment with atezolizumab (atezo) plus platinum/gemcitabine (plt/gem) vs placebo plus plt/gem in patients (pts) with metastatic urothelial carcinoma (mUC): Updated data from the IMvigor130 OS final analysis
- Authors
- Grande, E[Grande, Enrique]; Bamias, A[Bamias, Aristotelis]; Galsky, MD[Galsky, Matt D.]; Kikuchi, E[Kikuchi, Eiji]; Davis, ID[Davis, Ian D.]; Arranz, JA[Arranz, Jose A.]; Rezazadeh, A[Rezazadeh, Arash]; del Muro, XG[del Muro, Xavier Garcia]; Park, SH[Park, Se Hoon]; De Giorgi, U[De Giorgi, Ugo]; Alekseev, B[Alekseev, Boris]; Mencinger, M[Mencinger, Marina]; Izumi, K[Izumi, Kouji]; Puente, J[Puente, Javier]; Li, JR[Li, Jian-Ri]; Lee, C[Lee, Chooi]; Bernhard, S[Bernhard, Sandrine]; Nicholas, A[Nicholas, Alan]; Telliez, J[Telliez, Julie]; De Santis, M[De Santis, Maria]
- Issue Date
- 1-Jun-2023
- Publisher
- LIPPINCOTT WILLIAMS & WILKINS
- Citation
- JOURNAL OF CLINICAL ONCOLOGY, v.41, no.16
- Indexed
- SCIE
SCOPUS
- Journal Title
- JOURNAL OF CLINICAL ONCOLOGY
- Volume
- 41
- Number
- 16
- ISSN
- 0732-183X
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.